Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist

Laura Ciapponi, Domenico Maione, Ariane Scoumanne, Patrizia Costa, Morten Bagge Hansen, Morten Svenson, Klaus Bendtzen, Tonino Alonzi, Giacomo Paonessa, Riccardo Cortese, Gennaro Ciliberto, Rocco Savino

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Neutralization of cytokine activity by monoclonal antibodies or receptor antagonists is beneficial in the treatment of immune and neoplastic diseases, but the necessity for continuous parenteral delivery of these anticytokine agents poses considerable practical limitations. A viable alternative is to induce a neutralizing antibody response. Using transgenic mice with high circulating levels of human interleukin-6 (hIL-6), we show that injection of the hIL-6 receptor antagonist Sant1 (an IL-6 valiant with seven amino-acid substitutions) induces a strong anti-hIL-6 antibody response. The elicited antibodies bind circulating hIL-6 with very high affinity, totally masking it, and neutralize hIL-6 bioactivity both in vitro and in vivo.

Original languageEnglish
Pages (from-to)997-1001
Number of pages5
JournalNature Biotechnology
Volume15
Issue number10
Publication statusPublished - Oct 1997

Fingerprint

Interleukin-6 Receptors
Antibodies
Autoantibodies
Interleukin-6
Vaccination
Monoclonal antibodies
Antibody Formation
Bioactivity
Amino acids
Substitution reactions
Immune System Diseases
Amino Acid Substitution
Neutralizing Antibodies
Transgenic Mice
Monoclonal Antibodies
Cytokines
Amino Acids
Injections

Keywords

  • Autoantibody
  • Autoimmunity
  • Cytokine
  • Receptor antagonist

ASJC Scopus subject areas

  • Microbiology

Cite this

Ciapponi, L., Maione, D., Scoumanne, A., Costa, P., Hansen, M. B., Svenson, M., ... Savino, R. (1997). Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nature Biotechnology, 15(10), 997-1001.

Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. / Ciapponi, Laura; Maione, Domenico; Scoumanne, Ariane; Costa, Patrizia; Hansen, Morten Bagge; Svenson, Morten; Bendtzen, Klaus; Alonzi, Tonino; Paonessa, Giacomo; Cortese, Riccardo; Ciliberto, Gennaro; Savino, Rocco.

In: Nature Biotechnology, Vol. 15, No. 10, 10.1997, p. 997-1001.

Research output: Contribution to journalArticle

Ciapponi, L, Maione, D, Scoumanne, A, Costa, P, Hansen, MB, Svenson, M, Bendtzen, K, Alonzi, T, Paonessa, G, Cortese, R, Ciliberto, G & Savino, R 1997, 'Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist', Nature Biotechnology, vol. 15, no. 10, pp. 997-1001.
Ciapponi L, Maione D, Scoumanne A, Costa P, Hansen MB, Svenson M et al. Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nature Biotechnology. 1997 Oct;15(10):997-1001.
Ciapponi, Laura ; Maione, Domenico ; Scoumanne, Ariane ; Costa, Patrizia ; Hansen, Morten Bagge ; Svenson, Morten ; Bendtzen, Klaus ; Alonzi, Tonino ; Paonessa, Giacomo ; Cortese, Riccardo ; Ciliberto, Gennaro ; Savino, Rocco. / Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. In: Nature Biotechnology. 1997 ; Vol. 15, No. 10. pp. 997-1001.
@article{8a9d526c26c64b6994ba24ae72c85aa6,
title = "Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist",
abstract = "Neutralization of cytokine activity by monoclonal antibodies or receptor antagonists is beneficial in the treatment of immune and neoplastic diseases, but the necessity for continuous parenteral delivery of these anticytokine agents poses considerable practical limitations. A viable alternative is to induce a neutralizing antibody response. Using transgenic mice with high circulating levels of human interleukin-6 (hIL-6), we show that injection of the hIL-6 receptor antagonist Sant1 (an IL-6 valiant with seven amino-acid substitutions) induces a strong anti-hIL-6 antibody response. The elicited antibodies bind circulating hIL-6 with very high affinity, totally masking it, and neutralize hIL-6 bioactivity both in vitro and in vivo.",
keywords = "Autoantibody, Autoimmunity, Cytokine, Receptor antagonist",
author = "Laura Ciapponi and Domenico Maione and Ariane Scoumanne and Patrizia Costa and Hansen, {Morten Bagge} and Morten Svenson and Klaus Bendtzen and Tonino Alonzi and Giacomo Paonessa and Riccardo Cortese and Gennaro Ciliberto and Rocco Savino",
year = "1997",
month = "10",
language = "English",
volume = "15",
pages = "997--1001",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist

AU - Ciapponi, Laura

AU - Maione, Domenico

AU - Scoumanne, Ariane

AU - Costa, Patrizia

AU - Hansen, Morten Bagge

AU - Svenson, Morten

AU - Bendtzen, Klaus

AU - Alonzi, Tonino

AU - Paonessa, Giacomo

AU - Cortese, Riccardo

AU - Ciliberto, Gennaro

AU - Savino, Rocco

PY - 1997/10

Y1 - 1997/10

N2 - Neutralization of cytokine activity by monoclonal antibodies or receptor antagonists is beneficial in the treatment of immune and neoplastic diseases, but the necessity for continuous parenteral delivery of these anticytokine agents poses considerable practical limitations. A viable alternative is to induce a neutralizing antibody response. Using transgenic mice with high circulating levels of human interleukin-6 (hIL-6), we show that injection of the hIL-6 receptor antagonist Sant1 (an IL-6 valiant with seven amino-acid substitutions) induces a strong anti-hIL-6 antibody response. The elicited antibodies bind circulating hIL-6 with very high affinity, totally masking it, and neutralize hIL-6 bioactivity both in vitro and in vivo.

AB - Neutralization of cytokine activity by monoclonal antibodies or receptor antagonists is beneficial in the treatment of immune and neoplastic diseases, but the necessity for continuous parenteral delivery of these anticytokine agents poses considerable practical limitations. A viable alternative is to induce a neutralizing antibody response. Using transgenic mice with high circulating levels of human interleukin-6 (hIL-6), we show that injection of the hIL-6 receptor antagonist Sant1 (an IL-6 valiant with seven amino-acid substitutions) induces a strong anti-hIL-6 antibody response. The elicited antibodies bind circulating hIL-6 with very high affinity, totally masking it, and neutralize hIL-6 bioactivity both in vitro and in vivo.

KW - Autoantibody

KW - Autoimmunity

KW - Cytokine

KW - Receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=0030823269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030823269&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 997

EP - 1001

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 10

ER -